NCT04381871

Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients

Phase II ,III Randomized Double Blind Parallel Arms Clinical Trial of Potential Role of Gum Arabic ( Acacia Senegal) as Immunomodulatory Agent Among COVID 19 Patients in Sudan

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Al-Neelain University · Academic / Other
• Sex: All
• Age: 5 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo

Detailed description

Randomized placebo controlled trial including COVID 19 seropositive patients will be treated with 30 gram per day for 4 weeks, compared to placebo group treated for the same duration in positive COVID 19 patients. Blood samples will be taken first at base line level, after two weeks and after the intervention after satisfying the inclusion and exclusion criteria. The main objective is to assess the effect of Gum Arabic (acacia Senegal) on immune system among COVID-19 patients. The outcome of this project understand SARS-CoV-2 immune response in COVID patients and the effect of Gum Arabic (Acacia Senegal) consumption to counteract progression of the disease

Conditions

• COVID 19

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Acacia Senegal	Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
DIETARY_SUPPLEMENT	Pectin	Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks

Timeline

• Start date: 2020-06-01
• Primary completion: 2020-08-01
• Completion: 2020-09-01
• First posted: 2020-05-11
• Last updated: 2020-05-12

Locations

2 sites across 1 country: Sudan